SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AutoImmune-AIMM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: organ who wrote (38)3/15/1997 10:35:00 PM
From: Thomas Stewart   of 298
 
Are you suggesting that it is naive to suppose that investigator's don't know the results of double-blind clinical trials prior to breaking the code at the end of the study? I hope not. I would hope that a graduate student (not such a big difference, BTW, and I would go easy on the "colleague" stuff for now) would have more respect for the professional ranks that he intends to join.

Furthermore, Bill's remarks were right on, but he neglected to mention that the source, in addition to violating ethical norms, would also be violating security laws for which their may be CRIMINAL sanctions. That such information would cavalierly and reliably be passed along to a random graduate student at a conference, like so much gossip, is hard to believe. You should think about the credibility of the players in your information stream.

As for the value of the stock should the trials be unsuccessful, I think all the numbers I have seen in the last few posts are way too optimistic.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News